Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Rosai-Dorfman-Destombes disease, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
Which patients will regress spontaneously cannot be predicted.
Two thirds of cases have no identified driver mutation.
All systemic treatments rest on case series; there has never been a randomised trial.
Neurological disease can leave permanent deficits despite treatment.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 12 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Observation, because spontaneous regression is common.
Excisional biopsy with immunohistochemistry and MAPK pathway sequencing; FDG-PET/CT; MRI where neurological disease is suspected; immunoglobulins and autoimmune screen.
Cobimetinib (approved 2022 for histiocytic neoplasms) or trametinib.
Corticosteroids for rapid control; sirolimus with prednisone, cladribine, methotrexate or lenalidomide; rituximab for IgG4-associated disease.